ABBV vs ABNB Stock Comparison

Scores Breakdown

Metric	ABBV	ABNB
📈 Growth	26/30	14/30
💰 Profitability	18/20	18/20
🏦 Financial Health	6/20	16/20
💵 Valuation	12/20	13/20
⚠️ Risk (lower is better)	8/10	7/10
Overall Score	64/100	64/100

Side-by-Side Summaries

ABBV Analysis	ABNB Analysis
📈 Growth & Financial Trajectory Over the eight quarters, Revenues rose from about $14.46B (2024-Q2) to about $16.99B (2026-Q2). Net Income expanded from about $1.31B to about $3.62B, with quarterly fluctuations (notably a dip in 2025-Q2 before a robust rebound by 2026-Q2). 💰 Margins & Cash Flow Gross Profit was strong, and implied gross margins around the mid-to-high 70s percent, peaking around 75% in late 2025 and staying near that level in 2026-Q2 (e.g., $12.7B gross profit on $16.99B revenue). Operating income remained positive across the period, supporting a healthy but fluctuating margin structure. Net Cash Flow From Operating Activities stayed positive in all quarters, with peaks near $5.15B in 2025-Q4 and around $3.44B in 2026-Q2; investing and financing activities contributed to occasional cash outflows, resulting in negative total cash flow in several quarters. 🛡️ Balance Sheet & Liquidity Total assets ranged around $134-141B; liabilities aligned with asset base, yielding negative Equity in several periods (e.g., -$5.89B in 2026-Q2), signaling solvency risk despite strong operating cash flow. Current liabilities remain substantial, but liquidity from operating cash flow partially offsets near-term obligations. ⚠️ Key Drivers & Risks Drivers: Robust, diversified dermatology/immunology portfolio with steady cash generation; payer pricing power. Risks: Negative equity/leverage sensitivity to debt refinancing; regulatory/payer pressures and potential patent/exclusivity shifts.	📈 Growth & Financial Trajectory Over 8 quarters, Revenue declined modestly from $3.732B in Q3 2024 to $3.608B in Q2 2026, while Net Income rose from $461M to $816M, with a peak of $1.374B in Q3 2025 before a mid-year dip. This shows profitability resilience amid revenue variability, driven by episodic operating leverage. Overall, the growth signal is modest on revenue but improving on bottom-line momentum into Q2 2026. 💰 Margins & Cash Flow Gross Margin has remained high, generally in the mid to high 70s up to mid 80s percent across quarters. Operating Margin has been volatile, ranging from near-breakeven to about 39–61% in select quarters, recently around 21% in Q2 2026 as scale expands. Net cash flow from operating activities has been positive in most periods (e.g., ~$1.79B in Q1 2025; $1.27B in Q2 2026), with notable quarterly outflows in Q4 2025 (-$3.73B), reflecting seasonality and financing/investing activity. 🛡️ Balance Sheet & Liquidity Current assets consistently in the low 20s of billions vs current liabilities in the mid to high teens, yielding a healthy current ratio (~1.4–1.6). Long-term debt sits around $2.48B, with equity around $7.6–8.7B across periods, indicating modest leverage and solid equity base. Liabilities plus equity align with asset bases, suggesting liquidity resilience. ⚠️ Key Drivers & Risks Drivers: Travel demand resurgence; network effects and marketplace scale. Risks: Travel cyclicality and regulatory/commercial risk; valuation sensitivity to quarterly volatility and travel headlines.

ABBV Analysis

ABNB Analysis

📈 Growth & Financial Trajectory

Over the eight quarters, Revenues rose from about $14.46B (2024-Q2) to about $16.99B (2026-Q2). Net Income expanded from about $1.31B to about $3.62B, with quarterly fluctuations (notably a dip in 2025-Q2 before a robust rebound by 2026-Q2).

💰 Margins & Cash Flow

Gross Profit was strong, and implied gross margins around the mid-to-high 70s percent, peaking around 75% in late 2025 and staying near that level in 2026-Q2 (e.g., $12.7B gross profit on $16.99B revenue). Operating income remained positive across the period, supporting a healthy but fluctuating margin structure. Net Cash Flow From Operating Activities stayed positive in all quarters, with peaks near $5.15B in 2025-Q4 and around $3.44B in 2026-Q2; investing and financing activities contributed to occasional cash outflows, resulting in negative total cash flow in several quarters.

🛡️ Balance Sheet & Liquidity

Total assets ranged around $134-141B; liabilities aligned with asset base, yielding negative Equity in several periods (e.g., -$5.89B in 2026-Q2), signaling solvency risk despite strong operating cash flow. Current liabilities remain substantial, but liquidity from operating cash flow partially offsets near-term obligations.

⚠️ Key Drivers & Risks

Drivers: Robust, diversified dermatology/immunology portfolio with steady cash generation; payer pricing power.
Risks: Negative equity/leverage sensitivity to debt refinancing; regulatory/payer pressures and potential patent/exclusivity shifts.

📈 Growth & Financial Trajectory

Over 8 quarters, Revenue declined modestly from $3.732B in Q3 2024 to $3.608B in Q2 2026, while Net Income rose from $461M to $816M, with a peak of $1.374B in Q3 2025 before a mid-year dip. This shows profitability resilience amid revenue variability, driven by episodic operating leverage. Overall, the growth signal is modest on revenue but improving on bottom-line momentum into Q2 2026.

💰 Margins & Cash Flow

Gross Margin has remained high, generally in the mid to high 70s up to mid 80s percent across quarters.
Operating Margin has been volatile, ranging from near-breakeven to about 39–61% in select quarters, recently around 21% in Q2 2026 as scale expands.
Net cash flow from operating activities has been positive in most periods (e.g., ~$1.79B in Q1 2025; $1.27B in Q2 2026), with notable quarterly outflows in Q4 2025 (-$3.73B), reflecting seasonality and financing/investing activity.

🛡️ Balance Sheet & Liquidity

Current assets consistently in the low 20s of billions vs current liabilities in the mid to high teens, yielding a healthy current ratio (~1.4–1.6).
Long-term debt sits around $2.48B, with equity around $7.6–8.7B across periods, indicating modest leverage and solid equity base. Liabilities plus equity align with asset bases, suggesting liquidity resilience.

⚠️ Key Drivers & Risks

Drivers: Travel demand resurgence; network effects and marketplace scale.
Risks: Travel cyclicality and regulatory/commercial risk; valuation sensitivity to quarterly volatility and travel headlines.

Similar Companies

ABT Score: 71 AMGN Score: 67 BMY Score: 72 GILD Score: 46 JNJ Score: 86 LLY Score: 82 MRK Score: 58 MRNA Score: 38 PFE Score: 55

Top Rated Companies

View Top 20 →

TPL "Texas Pacific Land Corp"

MPWR "MONOLITHIC POWER SYSTEMS, INC."

AMD "ADVANCED MICRO DEVICES INC"

KO "COCA COLA CO"

TEL "TE Connectivity plc"